Company: CDT
Filing Date: 2025-12-12
Form Type: S-8 POS
Source: 0001493152-25-027522
Chunk: 7

Company: CDT Equity Inc.
Filing Date: 2025-12-12
Form: S-8 POS
Chunk 7
---
 the Common Stock began trading on The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis on October 13, 2025, at market open under the existing ticker symbol, “CDT”. As of the Effective Time, every 8 shares of the Company’s issued and outstanding Common Stock was combined into one share of Common Stock. The Reverse Stock Split did not affect the number of authorized shares of Common Stock or the par value of the Common Stock. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who would otherwise have been entitled to receive fractional shares as a result of the Reverse Stock Split were entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing price per share of the Common Stock (as adjusted to give effect to the Reverse Stock Split) on The Nasdaq Capital Market on October 13, 2025. All historical share and per-share amounts reflected throughout this Reoffer Prospectus are presented on a Reverse Stock Split-adjusted basis.

| 2 |

Equity Grants

On August 12, 2025, the Company granted an aggregate of 13,125 Shares to the Company’s three independent directors based on the closing price per share of the Company’s Common Stock as compensation for past services. The Shares were granted pursuant to the 2023 Plan and vested immediately upon grant.

On September 19, 2025, the Company granted an aggregate of 200,000 Shares to the Company’s Chief Executive Officer and Chief Financial Officer based on the closing price per share of the Company’s Common Stock on September 18, 2025 as compensation for past services. The Shares were granted pursuant to the 2023 Plan and vested immediately upon grant.

Corporate Information

On September 22, 2023 (the “Closing Date”), a merger transaction (the “Business Combination”) between Conduit Pharmaceuticals Limited (“Old Conduit”), Murphy Canyon Acquisition Corp (“MURF”) and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly owned subsidiary of MURF (“Merger Sub”), was completed pursuant to the initial merger agreement dated November 8, 2022 and subsequent amendments to the merger agreement dated January 27, 2023 and May 11, 2023 (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, on the Closing Date, (i) Merger Sub merged with and into Old Conduit, with